Guardant Health Company profile
Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers liquid biopsy tests for advanced stage cancer, such as Guardant360, a molecular diagnostic test that measures various cancer-related genes; and GuardantOMNI, a broader gene panel, including genes associated with homologous recombination repair deficiency and biomarkers for immuno-oncology applications. It also provides LUNAR-1 for minimal residual disease and recurrence detection in cancer survivors. In addition, the company is developing LUNAR-2 for early detection of cancer in higher risk individuals. Further, it offers development services, including companion diagnostic development and regulatory approval, clinical trial referral, and liquid biopsy testing development and support services to biopharmaceutical companies and medical institutions. Guardant Health, Inc. was incorporated in 2011 and is headquartered in Redwood City, California. Gasoline petrol price forecast 2025-2030: Third-party price targetDiscover third-party gasoline (petrol) price predictions for 2025 and beyond, with analyst targets, historical prices, and trading strategies.
16:34, 27 February 2025
Is momentum in US stocks changing?Us stocks continue to face bearish pressure as uncertainties persist, but is the long-term momentum turning?
11:13, 26 February 2025
Gold eyes $3,000 as safe-haven demand remains robustGeopolitical uncertainty continues to drive appetite for gold as XAU/USD nears the $3,000 level.
15:02, 24 February 2025
WTI selloff halts at $70: will further bearishness prevail?US crude prices attempt to rebound on Monday as talks about increased production in Kurdistan weigh on prices.
14:30, 24 February 2025